Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 2, 2007, Pages 98-107

  Rosenstock, Julio ^a   Zinman, Bernard ^b  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Sitagliptin; Vildagliptin

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; METFORMIN; PHX 1149; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; ARTHRALGIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES CONTROL; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANTIGENS, CD26; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; PROTEASE INHIBITORS;

EID: 33847685714     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3280a02f65     Document Type: Review

References (70)

1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287:360-372.
2. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18:430-441.
3. Reimer MK, Holst JJ, Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146:717-727.
4. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36:867-876.
5. Drucker D. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26:2929-2940.
6. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004; 13:1091-1102.
7. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004; 36:747-754.
8. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol 2006; 31:133-147.
9. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006; 29:435-449. Comprehensive review on GLP-1 mimetics and analogues' clinical data.
10. Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006; 15:431-442.
11. Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004; 36:775-781.
12. Ahrén B. Type 2 diabetes, insulin secretion and b cell mass. Curr Mol Med 2005; 5:275-286.
13. Dunning BE, Foley JE, Ahrén B. α-Cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48:1700-1713.
14. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004; 53:624-632.
15. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88:2300-2308.
16. Butler AE, Janson J, Bonner-Weir S, et al. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110.
17. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38:665-673.
18. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101:515-520.
19. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144:5140-5158.
20. Buse JB, Henry RR, Han J, et al., for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628-2635.
21. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100.
22. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28:1083-1091.
23. Madsbad S, Schmitz O, Ranstam J, et al., NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27:1335-1342.
24. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subject with type 2 diabetes. Diabetes 2006; 55 (Suppl 1):A462; abstract A27-A28, abstract 115-OR.
25. Drucker DJ, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705. Very scholarly review on the physiologic mechanisms of GLP-1 agonists and DPP-4 inhibitors and potential therapeutic value.
26. Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006; 8:385-396.
27. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60:1454-1470. Thorough pharmacologic review on DPP-4 inhibitors.
28. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPPIV. Crit Rev Clin Lab Sci 2003; 40:209-294.
29. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54:2988-2994.
30. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44:1126-1131.
31. Deacon CF, Nauck MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85:3575-3581.
32. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80:952-957.
33. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes 1998; 47:764-769.
34. Deacon CF, Danielsen P, Klarskov L, et al. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001; 50:1588-1597.
35. Deacon CF, Wamberg S, Bie P, et al. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172:355-362.
36. Deacon CF. MK-431 (Merck). Curr Opin Investig Drugs 2005; 6:419-426.
37. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46:876-886.
38. Herman G, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91:4612-4619.
39. He Y-L, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes. J Clin Pharmacol In press.
40. Miller SA, Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006; 40:1336-1343.
41. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases apoptosis [abstract P572]. Diabetes 2005; 54 (suppl 1):A141.
42. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55:1695-1704.
43. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-Hydroxyl-1- adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46:2774-2789.
44. Burkey BF, Russell M, Wang K, et al. Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9 [abstract 1995-PO]. Diabetologia 2006; 49 (suppl 1):477.
45. Hughes TE, Mone MD, Russell ME, et al. NVP-DPP728(1-[[[2-[(5- cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(s)-pyrrolidine, a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999; 38:11597-11603.
46. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[ 1,2,4]thiazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48:141-151.
47. He YL, Sabo R, Wang Y. Influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin [abstract PIII-19]. J Clin Pharmacol 2006; 79:63.
48. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28:55-72.
49. Scott R, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI) [abstract 1997-PO]. Diabetes 2006; 55 (suppl 1):A462.
50. Herman G, Bergman A, Sagner A. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic profile and the propensity for drug-drug interactions [abstract 0795]. Diabetologia 2006; 49 (suppl 1):477.
51. Ahrén B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:2078-2084.
52. Mari A, Sallas M, He YL, et al. Vildagliptin, a dipetidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90:4888-4894.
53. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49:2049-2057.
54. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29:2632-2637.
55. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; In press.
56. Pi-Sunyer XF, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007; [Epub ahead of print]
57. Herman G, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes [abstract 541-P]. Diabetes 2005; 54 (suppl 1):A134.
58. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin and monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564-2571.
59. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30:217-223. Head-to-head study demonstrating that vildagliptin has equivalent glycemic control to thiazolidinediones but without weight gain
60. 1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM) [abstract 120-OR]. Diabetes 2006; 55 (suppl 1):A29.
61. Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF 237 in metformin-treated patients with Type 2 diabetes. Diabetes Care 2004; 27:2874-2880.
62. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; [Epub ahead of print] Randomized study of vildagliptin added to metformin.
63. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638-2643. Randomized study of sitagliptin added to metformin.
64. 1c goal attainment in patients with type 2 diabetes mellitus (T2DM). Diabet Med 2006; 23(Suppl 4):319. Randomized study of combination sitagliptin plus metformin as first-line treatment compared with each monotherapy component.
65. Nauck MA, Meininger G, Sheng D, et al. for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, versus the sulfonylurea, glipizide, in patients with type 2 diabetes with inadequate glycemic control on metformin alone: a randomized, double-blind, noninferiority trial. Diabetes Obes Metab 2007; 9:194-205.
66. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556-1568. Randomized study of sitagliptin added to pioglitazone.
67. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9:166-174. Randomized study of vildagliptin added to pioglitazone.
68. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; In press. Randomized study of combination vildagliptin and pioglitazone as first-line therapy compared with each monotherapy component.
69. Fonseca V, Dejager S, Albrecht D, et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM) [abstract 467-P]. Diabetes 2006; 55(suppl 1):A111.
70. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-1972. Important initial guidelines from the American Diabetes Association and the European Association for the Study of Diabetes for management of type 2 diabetes, giving specific target-driven treatment options that should expand and evolve as clinical experience and outcome data with the new therapeutic agents mature and become available.